Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα

Nasui Wang,1,2* Seung-Hyun Ko,1,2* Weidong Chai,1 Guolian Li,1 Eugene J. Barrett,1 Lijian Tao,2 Wenhong Cao,4 and Zhenqi Liu1

1Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia; 2Department of Medicine, Central South University Xiangya Hospital, Hunan, China; 3Division of Endocrinology and Metabolism, Department of Internal Medicine, the Catholic University of Korea, Seoul, Korea; and 4The Endocrine Biology Program, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina

Submitted 13 July 2010; accepted in final form 22 October 2010

Wang N, Ko S, Chai W, Li G, Barrett EJ, Tao L, Cao W, Liu Z. Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα. Am J Physiol Endocrinol Metab 300: E195–E201, 2011. First published October 26, 2010; doi:10.1152/ajpendo.00414.2010.—Resveratrol, a polyphenol found in many plants, has antioxidant and anti-inflammatory actions. It also improves endothelial function and may be cardioprotective. Tumor necrosis factor-α (TNFα) causes oxidative stress and microvascular endothelial dysfunction. Whether resveratrol affects microvascular function in vivo and, if so, whether inflammatory cytokines antagonize its microvascular action are not clear. In cultured bovine aortic endothelial cells (BAECs), resveratrol (100 nM) increased the phosphorylation of protein kinase B (Akt), endothelial nitric oxide (NO) synthase (eNOS), and ERK1/2 within 15 min by more than twofold, and this effect lasted for at least 2 h. Treatment of BAECs with TNFα (10 ng/ml) significantly increased the NADPH oxidase activity and the production of hydrogen peroxide and superoxide. Pretreatment of cells with resveratrol (100 nM) prevented each of these. Injection (ip) of resveratrol in rats potently increased muscle microvascular blood volume (MBV; P = 0.007) and flow (MBF; P < 0.02) within 30 min, and this was sustained for at least 2 h. The phosphorylation of Akt in liver or muscle was unchanged. Superimposed systemic infusion of l-NAME (NOS inhibitor) completely abolished resveratrol-induced increases in MBV and MBF. Similarly, systemic infusion of TNFα prevented resveratrol-induced muscle microvascular recruitment. In conclusion, resveratrol activates eNOS and increases muscle microvascular recruitment via an NO-dependent mechanism. Despite the potent antioxidant effect of resveratrol, TNFα at concentrations that block insulin-mediated muscle microvascular recruitment completely neutralized resveratrol’s microvascular action. Thus, chronic inflammation, as seen in type 2 diabetes, may limit resveratrol’s vasodilatory actions on muscle microcirculation.

* These authors contributed equally.

Address for reprint requests and other correspondence: Z. Liu, Div. of Endocrinology and Metabolism, Dept. of Medicine, Univ. of Virginia Health System, P. O. Box 801410, Charlottesville, VA 22908 (e-mail: zl3e@virginia.edu).

http://www.ajpendo.org 0193-1849/11 Copyright © 2011 the American Physiological Society E195
tion was blocked by TNFα despite the potent antioxidant effect of resveratrol.

MATERIALS AND METHODS

Culture of bovine arterial endothelial cells. Bovine arterial endothelial cells (BAECs) in primary culture were purchased from Cambrex BioSciences (Walkersville, MD) and cultured in endothelial basic medium supplemented with 5% fetal bovine serum, bovine brain extract, human epidermal growth factor (10 ng/ml), gentamicin sulfate (50 μg/ml), and hydrocortisone (1 μg/ml). Cells (passages 3–8) were grown to confluence and then used for experiments after serum starvation for 14 h. Cells were incubated with resveratrol (100 nM; Sigma-Aldrich, St. Louis, MO) in the absence or presence of TNFα (10 ng/ml; R & D Systems, Minneapolis, MN) for various amounts of time and then used for either Western blotting or measurement of hydrogen peroxide, superoxide anion, or NADPH oxidase activity.

Western blotting. Cells were lysed in ice-cold lysis buffer (50 mM Tris·HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM NaF, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride) and used for Western blotting, as described previously (4, 21, 22). The membranes were probed with antibodies against phospho-eNOS (Ser177), phospho-ERK1/2 (Thr202/Tyr204; Cell Signaling Technology, Danvers, MA), or phospho-Akt1 (Ser473; Upstate Biotechnology, Lake Placid, NY), and the autoradiographic films were scanned and quantified using enhanced chemiluminescence (Amersham Life Science, Piscataway, NJ), and the autoradiographic films were scanned and quantified using ImageQuant TL (Bio-Rad).

Measurement of hydrogen peroxide production. Endothelial production of hydrogen peroxide (H2O2) was measured with the fluorescent probe 5(6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate-acetyl ester (CM-H2DCFDA; Molecular Probes, Eugene, OR). In brief, BAECs (1 × 105/0.2 ml culture medium) were plated in 96-well microplates, grown to confluence, and incubated with CM-H2DCFDA (10 μM) at 37°C for 30 min. The fluorescence intensity was measured using a Wallac 1420 Victor2 multilabel counter (excitation 485 nm, emission 535 nm; Wallac, Turku, Finland), and background-subtracted video intensity in the region of interest was determined as described previously (24, 25, 40, 41). The PI (time) vs. video-intensity curve was generated and fitted to an exponential function: \[ y = A(1 - e^{-Bt}), \] where \( y \) is video intensity at \( t \), \( A \) is the plateau video intensity representing MBV, and \( B \) is the rate constant, which reflects the rate of rise of video intensity (i.e., MFB). MFB is the product of MBV and MFB.

Throughout the study, MAP and heart rate were monitored via a sensor connected to the carotid arterial catheter (AD Instruments, Colorado Springs, CO). Pentobarbital sodium was infused at a variable rate to maintain steady levels of anesthesia and blood pressure throughout the study. Euthermia was maintained with a heating pad. Arterial blood glucose concentrations were determined using an Accu-Check Advantage blood glucometer (Roche).

Statistical analysis. All data are presented as means ± SE. Statistical analyses were performed using Sigma Stat 3.1.1 software (Systat Software), using one-way ANOVA with post hoc Dunn’s analysis, or unpaired Student’s t-test as appropriate. A P value of <0.05 was considered statistically significant.

RESULTS

Resveratrol stimulates phosphorylation of endothelial Akt, eNOS, and ERK1/2 in vitro. To examine the effects of resveratrol on the phosphorylation of Akt, eNOS, and
ERK1/2 in endothelial cells, BAECs were cultured to confluence and then treated with 100 nM resveratrol for various times after an overnight fast. We first carried out a dose response study and found that resveratrol at 100 nM potently increased the phosphorylation of Akt and eNOS by 30 min of incubation (Fig. 1A). Using this concentration, we examined the time course of resveratrol on endothelial Akt, eNOS, and ERK1/2 phosphorylation. As shown in Fig. 1, B and C, resveratrol treatment acutely increased the phosphorylation of Akt, eNOS, and ERK1/2 within 15 min by more than twofold, and this effect lasted for ≥2 h.

Resveratrol abolishes TNFα-induced ROS production and NADPH oxidase activity in endothelial cells. Resveratrol is a potent antioxidant and has been shown to prevent TNFα-induced ROS production in endothelial cells. To ascertain that resveratrol does decrease TNFα-induced ROS and NADPH oxidase activity, we incubated BAECs with TNFα in the presence or absence of resveratrol. As shown in Fig. 2, TNFα potently increased the endothelial production of H2O2 (P < 0.002) and superoxide anion (P < 0.02) and increased the NADPH oxidase activity (P < 0.004). However, treatment with resveratrol at the same time completely restored the levels of H2O2 and superoxide anion and the activity of NADPH oxidase back to the control levels.

Resveratrol increases muscle microvascular perfusion in vivo via NO-dependent pathway. To assess the physiological significance of the resveratrol-induced eNOS phosphorylation, we next carried out in vivo studies examining the effects of resveratrol on muscle microvascular perfusion, since previous studies have shown repeatedly that activation of eNOS by insulin potently increases muscle microvascular perfusion by increasing MBV without affecting MFV (9, 10, 25, 36–38). As shown in Fig. 3, ip resveratrol potently increased muscle MBV at 30 min, and this effect lasted for ~120 min (P = 0.007, ANOVA). Although MFV trended up after resveratrol injection, the increase was not statistically significant (P = 0.233). As a result, MBF, which is derived from the product of MBV and MFV, increased significantly after resveratrol injection (P < 0.02). Resveratrol clearly increased MBF without inducing significant changes in either MAP or blood glucose concentrations (Table 1).

Because a previous study has confirmed that resveratrol enhances NO release and improves endothelial function in diabetic mice (44), and increased NO availability by either insulin infusion (36, 37, 45) or losartan injection (5) potently increases MBV, we further examined the role of NO in resveratrol-induced increase of muscle MBV. As shown in Fig. 3, continuous infusion of L-NAME, a selective NOS inhibitor, completely abolished resveratrol-induced increases in MBV and MBF (P = 0.122 and 0.073, respectively; Fig. 3). As expected, continuous infusion of L-NAME at this dose raised the MAP by ~20 mmHg (P < 0.001; Table 1) without affecting blood glucose levels.

Resveratrol does not increase the phosphorylation of Akt in either liver or muscle in vivo. Because we have shown that resveratrol increases the phosphorylation of Akt in cultured endothelial cells, we further examined whether resveratrol also stimulated the phosphorylation of Akt in liver and muscle. We selected these tissues because liver has a high blood flow and discontinuous endothelium, allowing easy access to the hepa-
tocyte, whereas muscle has tight endothelial junctions. As shown in Fig. 4, resveratrol did not increase the phosphorylation of Akt in either tissue, suggesting that the resveratrol effect is relatively endothelium specific in our study setting. TNFα abolishes resveratrol-induced increases in muscle microvascular perfusion. Chronic inflammation contributes to endothelial dysfunction. Although resveratrol restores vascular function in diabetic mice, the improvement is abolished by incubating the vessel with TNFα in vitro (44). To further examine whether TNFα impairs the vasodilatory effect of resveratrol on muscle microcirculation, we systemically infused TNFα at a concentration that has been shown to abolish insulin-mediated capillary recruitment in rats 60 min prior to resveratrol ip injection. TNFα infusion had no significant effect on MAP or blood glucose concentrations (Table 1) but completely reversed resveratrol-induced increases in skeletal muscle MBV and MBF (P = 0.659 and 0.834, respectively; Fig. 3).

**DISCUSSION**

The present study demonstrated for the first time that resveratrol exerts potent vasodilatory action in the skeletal muscle microcirculation via a NO-dependent mechanism. Despite the potent antioxidant effect of resveratrol, TNFα infusion completely neutralized resveratrol’s microvascular vasodilatory actions. Because it is in the microcirculation where substrate extraction takes place and a relatively small increase (decrease)
in the microvascular surface area could markedly increase (decrease) substrate extraction by muscle, antioxidants like resveratrol may play an important role in regulating substrate exchange in the muscle by increasing endothelial surface area.

Resveratrol has been shown to have multiple potential health benefits, including cardiovascular protection (3). Although the underlying mechanisms remain to be elucidated, evidence suggests that this might be related to resveratrol’s antioxidant and anti-inflammatory properties and its ability to improve endothelial function (3). Resveratrol can relax isolated murine aorta or porcine mesenteric and uterine arteries (6, 27). It appears that both endothelium-dependent (NO-mediated; Refs. 28 and 33) and endothelium-independent (Ca++-activated K+ channels; Ref. 23) pathways are involved in resveratrol-induced vascular relaxation. In the present study, we observed that L-NAME completely abolished resveratrol-mediated muscle microvascular recruitment in vivo. This strongly suggests that resveratrol increases muscle microvascular perfusion via the endothelium-dependent, NO-mediated process. The observation that resveratrol increased eNOS phosphorylation within 15 min and recruited microvasculature within 30 min suggests that resveratrol can acutely activate eNOS to increase NO production. This is consistent with a previous report showing that resveratrol induced endothelial NO production after only a 2-min incubation (39). In addition, longer treatment with resveratrol upregulated eNOS mRNA and protein expression, increased eNOS promoter activity, and stabilized eNOS mRNA in cultured human umbilical vein endothelial cells (39). Resveratrol appears to affect eNOS via SIRT1 to cause upregulation and deacetylation (26) and perhaps also via ERK to induce eNOS phosphorylation, which is mediated by ERK1/2 (19, 20).

The effect of resveratrol on the muscle microcirculation resembles that of physiological concentrations of insulin. We and others have demonstrated repeatedly that insulin at physiological concentrations potently recruits microvasculature in muscle in both humans and experimental animals (9, 11, 24, 25, 36–38, 45). This is mediated via the Akt-eNOS signaling pathway. Although we did not measure insulin concentrations in the present study, it is unlikely that resveratrol exerted its actions via insulin secretion since plasma glucose concentrations remained steady during the study, and there was no evidence of increased Akt phosphorylation in biopsies of either skeletal muscle or liver following resveratrol treatment (Fig. 4). Furthermore, in vitro studies have shown that resveratrol actually inhibits insulin release, likely by blocking the voltage-gated Ca++ channels (18, 34).

That resveratrol increased muscle microvascular blood flow by more than twofold without significantly changing plasma glucose concentrations is not surprising, since the basal use of glucose by muscle is low and the increased glucose use associated with the muscle microvascular recruitment is likely less than the hepatic glucose production in the postabsorptive state. Similarly, we have demonstrated previously that increasing muscle microvascular recruitment and muscle glucose use by threefold after losartan administration does not alter plasma glucose concentrations (5).

Endothelial dysfunction is an early event in the development of atherosclerosis and is closely associated with insulin resistance, obesity, and diabetes. Many factors are associated with endothelial dysfunction, including chronic inflammation. Resveratrol treatment has been shown to improve endothelial function in hypertensive rats (31), in rats fed high-fat diet (1), and in diabetic mice (44). This is not surprising since resveratrol has been shown to have potent antioxidant and anti-inflammatory properties, likely via its effect on the NADPH oxidase (7, 33, 44). Consistent with previous reports, we have shown in the present study that resveratrol prevented TNFα-

Table 1. Changes in MAP and blood glucose during the in vivo studies

<table>
<thead>
<tr>
<th></th>
<th>Basal</th>
<th>30 min</th>
<th>60 min</th>
<th>90 min</th>
<th>120 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>107 ± 5</td>
<td>99 ± 4</td>
<td>100 ± 3</td>
<td>100 ± 3</td>
<td>100 ± 4</td>
</tr>
<tr>
<td>Resveratrol</td>
<td>111 ± 2</td>
<td>104 ± 4</td>
<td>106 ± 4</td>
<td>104 ± 4</td>
<td>101 ± 4</td>
</tr>
<tr>
<td>Resveratrol + l-NAME</td>
<td>113 ± 4</td>
<td>125 ± 4*</td>
<td>130 ± 4*</td>
<td>133 ± 4*</td>
<td>130 ± 2*</td>
</tr>
<tr>
<td>Resveratrol + TNF-α</td>
<td>114 ± 4</td>
<td>109 ± 4</td>
<td>104 ± 4</td>
<td>106 ± 3</td>
<td>109 ± 3</td>
</tr>
<tr>
<td>Blood glucose, mg/dl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>98 ± 6</td>
<td>93 ± 8</td>
<td>96 ± 5</td>
<td>101 ± 6</td>
<td>107 ± 7</td>
</tr>
<tr>
<td>Resveratrol</td>
<td>101 ± 1</td>
<td>91 ± 4</td>
<td>101 ± 3</td>
<td>96 ± 4</td>
<td>102 ± 4</td>
</tr>
<tr>
<td>Resveratrol + l-NAME</td>
<td>90 ± 3</td>
<td>86 ± 2</td>
<td>88 ± 3</td>
<td>92 ± 3</td>
<td>98 ± 4</td>
</tr>
<tr>
<td>Resveratrol + TNFα</td>
<td>107 ± 2</td>
<td>109 ± 5</td>
<td>107 ± 5</td>
<td>111 ± 5</td>
<td>113 ± 4</td>
</tr>
</tbody>
</table>

Values are means ± SE. MAP, mean arterial blood pressure; l-NAME, Nω-nitro-l-arginine methyl ester. *P < 0.001.

![AJP-Endocrinol Metab • VOL 300 • JANUARY 2011 • www.ajpendo.org](http://ajpendo.physiology.org/)

![Fig. 4. Effects of resveratrol on Akt phosphorylation in liver and muscle in vivo. A: representative gels. L1 and L2, liver samples 1 and 2, respectively; M1 and M2, muscle samples 1 and 2, respectively. B: quantification of Akt phosphorylation.](http://ajpendo.physiology.org/)
induced increases in NADPH oxidase activity and ROS production (Fig. 2).

In the present study, we observed that TNFα completely neutralized the vasodilatory actions of resveratrol on muscle microvasculature (Fig. 3). TNFα at the dose infused increased plasma TNFα concentrations to ~350 pg/ml (46) and did not affect basal hemodynamic parameters, glucose metabolism, or muscle microvascular perfusion (43). However, this dose was clearly enough to completely block muscle microvascular recruitment induced by physiological hyperinsulinemia. Although this concentration is higher than ~90 pg/ml observed in obese, insulin-resistant rodents (16), it is likely comparable with tissue concentrations, since most TNFα is released from various tissues. Indeed, in fructose-fed rats, each gram of skeletal muscle contains ~500–600 pg of TNFα (35). Further studies are warranted to elucidate the mechanisms underlying the inhibitory effect of TNFα on resveratrol-mediated muscle microvascular recruitment. Compared with the in vitro studies the TNFα concentration was 30-fold less, and resveratrol concentrations were fourfold higher. As such, it is reasonable to assume that resveratrol prevented TNFα-induced ROS production in vivo as well. However, it is likely that TNFα still stimulates some superoxide production, which then interacts with NO to form peroxynitrite, resulting in decreased NO bioavailability (42). It is also possible that TNFα may act via ROS-independent mechanisms. We have demonstrated previously that TNFα potently activates p38 MAPK, which subsequently causes serine phosphorylation of insulin receptor substrate-1 and impairs insulin-stimulated activation of Akt and eNOS in cultured endothelial cells (21). Whether TNFα attenuates resveratrol’s effect on muscle microvasculature via a similar mechanism warrants further study. Our results suggest that chronic inflammation, as seen in patients with diabetes, may limit resveratrol’s vasodilatory effect in the muscle microcirculation. Interestingly, in arteries isolated from humans with coronary heart disease, NO-dependent vasorelaxation in response to resveratrol is also lost (12).

At the dose (25 mg/kg ip) selected, plasma resveratrol concentrations reach ~100 ng/ml (~0.4 μM) at 120 min (47), which is similar to those achieved with intravenous injection (15). This was significantly lower than previous studies demonstrating potential health benefits of resveratrol (1–100 μM) (3). At this concentration, we were able to show that resveratrol potently recruited muscle microvasculature in vivo and abolished high concentrations of TNFα-induced increases in NADPH oxidase activity and ROS production in vitro. Whether resveratrol at lower concentrations has similar effects warrants further studies.

In conclusion, resveratrol acutely activates eNOS and recruits muscle microvasculature via an NO-dependent mechanism. Despite the potent antioxidant effect of resveratrol, TNFα at concentrations that block insulin-mediated muscle microvascular recruitment completely neutralized resveratrol’s microvascular action. Thus, our results suggest that chronic inflammation, as seen in type 2 diabetes, may limit resveratrol’s vasodilatory actions on muscle microvasculature.

GRANTS

This work was supported by American Diabetes Association Grants 7-07CR-34 and 7-09-NOVO-11 (Z. Liu) and National Institutes of Health Grants R01-HL-094722 (Z. Liu), R01-DK-057878 (E. J. Barrett), and R01-073759 (E. J. Barrett).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

REFERENCES


Downloaded from http://ajpendo.physiology.org/ by 10.220.33.5 on July 10, 2017
RESVERATROL AND MICROVASCULAR RECRUITMENT


